CompletedPhase 3NCT01681953
A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis
Studying Alpha-mannosidosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Zymenex A/S
- Principal Investigator
- Allan M Lund, MDCopenhagen University Hospital, Center for Metabolic Diseases, Department for Clinical Genetics
- Intervention
- Lamazym(drug)
- Enrollment
- 25 enrolled
- Eligibility
- 5-35 years · All sexes
- Timeline
- 2012 – 2014
Study locations (6)
- Center for Metabolic Diseases, Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen, Denmark
- Hôpital Femme Mère Enfant, Lyon, 59 boulevard Pinel, Bron, France
- Hôpital Trousseau, Service de neuropédiatrie, Centre Référence des Maladies Lysosomales, 26 avenue du Docteur Arnold Netter, Paris, France
- Universitätsmedizin Mainz, Zentrum für Kinder- und Jugendmedizin, Langenbeckstrasse 1, Mainz, Germany
- The Children's Memorial Health Institute Warsaw, Department of Metabolic Diseases, Al Dzieci Polskich 20, Warsaw, Poland
- Genetic Medicine, 6th floor, St Mary's Hospital, Oxford Road,, Manchester, United Kingdom
Collaborators
European Commission
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01681953 on ClinicalTrials.govOther trials for Alpha-mannosidosis
Additional recruiting or active studies for the same condition.